Table 1.

Reported cutaneous manifestations in immunocompromised patients, 1996 to 2011^a

Reference	Age of patient (yr)/sex	Underlying disease(s)	Country	Treatment	Outcome	Duration of treatment
8	48/M	IgA deficiency	Germany	CLR, RB, E	Resolved	6 mo
22	59/M	Renal transplant	Brazil	CLR, CI	Resolved	1 yr
114	52/M	Renal transplant	United States	CI, CLR	Resolved	1 yr
119	62/M	Heart transplant	Israel	CI, CLR, R	Regression within 3 wk	1 mo
72	65/F	CLL	United States	R,CLR, CI	Resolved	6 mo
72	17/F	SLE, MDS	United States	R, CLR, G	Resolved	NA
28	45/F	Renal transplant	Venezuela	CLR	Resolved	6 mo
28	14 mo/F	Unknown immunodeficiency, CD4+ <16%	Venezuela	CLR, TMS, R, I	Resolved	6 mo
125	67/F	RA	Germany	(i) CLR, CI; (ii) RB, E, CLR; (iii) CLR monotherapy after 8 wk	Resolved	>6 mo, NA
94	38/F	Autoimmune cirrhosis	United States	CI, CLR	Resolved	6 mo
94	47/F	Myasthenia gravis, corticosteroids	United States	D, RB, AZI	Improvement	8 mo
20	37/M	AIDS	Spain	I, R, E, AK, CLR, CI, Min	Resolved	5 mo
21	16/M	Renal transplant	United States	E, R, CLR, CI, AK	Partial resolution	14mo
149	59/M	Polymyalgia rheumatica	Germany	I, E, R	Died
53	27/F	AIDS	United States	RB, CLR, CI	Improvement	1 mo
138	59/F	SLE	Singapore	(i) CLR, CI, R, I, E; (ii) RB, CLR	Resolved; recurrence and resolution after 2nd course	13 mo
138	64/F	Cutaneous vasculitis	Singapore	CLR, CI	Resolution	18 mo
138	42/F	Sjogren's syndrome, Crohn's disease	Singapore	CLR, D	NA	18 mo
98	51/M	AIDS	Italy	RB, E, CLR; later RB, AZI, L	Resolution	5 mo
85	44/M	Renal transplant	Taiwan	CI, R, CLR	Resolution	1 yr
49	59/M	Diabetes	United States	CI, RB, CLR	Resolution	NA
139	25/F	SLE	Singapore	CLR, E, I, R	Resolution	6 mo
108	30/F	AIDS	Germany	Only antiretroviral therapy	Resolution	14 mo
38	51/M	AIDS	Japan	CLR, E	Resolution	8 mo
126	29/F	AIDS	United States	R, CI, CLR, D	Died	11 mo
47	62/M	AIDS	Switzerland	AZI, RB	Resolution	6 mo
51	51/M	AIDS	United States	CLR, TMS, CI	Resolution	NA
97	56/M	Lung transplant	Australia	I, CLR, P, D, CI	Resolution	42 mo
97	49/F	Lung transplant	Australia	CLR, E, R	Resolution	17 mo
97	53/F	Lung transplant	Australia	CLR, R, CI, D	Resolution	31 mo
97	39/M	Lung transplant	Australia	CLR, R, CI, D	Resolution	18 mo
80	30/F	AIDS	The Netherlands	(i) D, CI, R, CLR; (ii) Min, RB, E; (iii) I, CI, CY	Resolution	6 mo
6	35/M	AIDS	Germany	R, E, I, CLR	Resolution	7 wk, relapse and retreatment with same regimen

^aI, isoniazid; R, rifampin; RB, rifabutin; E, ethambutol; CY, cycloserine; CI, ciprofloxacin; AK, amikacin; AZI, azithromycin; CLR, clarithromycin; TMS, trimethoprim-sulfamethoxazole; P, pyrazinamide; D, doxycycline; Min, minocycline; G, gatifloxacin; L, levofloxacin; RA, rheumatoid arthritis; MDS, myelodysplastic syndrome; SLE, systemic lupus erythematosus; CLL, chronic lymphocytic leukemia; NA, data not available; M, male; F, female.